
|Articles|May 15, 2004
Moderate glaucoma best served by aggressive IOP-lowering efforts
London-The Early Manifest Glaucoma Trial (EMGT) provides a unique set of data for the natural history of moderate glaucoma and demonstrates that lowering IOP by 25% protects against progression of visual field loss, according to Roger A. Hitchings, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Development of maculopathy associated with systemic medications
2
Evolving glaucoma therapy: A new era of interventional strategies
3
STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
4
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study
5
 
 
















































.png)


